Form 8-K - Current report:
SEC Accession No. 0001104659-24-101327
Filing Date
2024-09-19
Accepted
2024-09-19 16:01:11
Documents
13
Period of Report
2024-09-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2424205d1_8k.htm   iXBRL 8-K 22614
  Complete submission text file 0001104659-24-101327.txt   195074

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rigl-20240916.xsd EX-101.SCH 3006
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE rigl-20240916_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rigl-20240916_pre.xml EX-101.PRE 22353
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2424205d1_8k_htm.xml XML 3700
Mailing Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-624-1100
RIGEL PHARMACEUTICALS INC (Filer) CIK: 0001034842 (see all company filings)

EIN.: 943248524 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-29889 | Film No.: 241310411
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)